发明名称 |
MODIFIED TRANSFERRIN FUSION PROTEINS |
摘要 |
<p>The present invention discloses fusion proteins comprising transferrin, lactoferrin or melanotransferrin fused to glucagon-like peptide 1 (GLP-1). In one embodiment of the invention, the fusion protein displays increased serum half-life as compared to a GLP-1 peptide in an unfused state. The invention includes a pharmaceutical composition comprising the GLP-1 fusion protein of the invention and a carrier. The fusion protein of the invention can be administered to a subject for treatment of diseases or conditions treatable by GLP-1, including, but not limited to, diabetes, obesity, congestive heart failure and inflammatory bowel syndrome.</p> |
申请公布号 |
EP1611093(B1) |
申请公布日期 |
2015.07.15 |
申请号 |
EP20030749159 |
申请日期 |
2003.08.28 |
申请人 |
BIOREXIS PHARMACEUTICAL CORPORATION |
发明人 |
PRIOR, CHRISTOPHER, P.;LAI, CHAR-HUEI;SADEGHI, HOMAYOUN;TURNER, ANDREW, J. |
分类号 |
A61K38/40;A61K38/00;A61K38/16;A61K38/41;A61K47/48;C07K7/06;C07K7/08;C07K14/705;C07K14/79 |
主分类号 |
A61K38/40 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|